Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy.
Second-generation vaccines will need to elicit neutralizing antibodies against sites that are …

Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2
spike protein are among the most promising approaches against COVID-19,. A bispecific …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic.
Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …

Severe acute respiratory syndrome coronavirus-2 (SAR-CoV-2) causes coronavirus disease
2019 (COVID19) that is responsible for short and long-term disease, as well as death, in …

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …

Mutations and transient conformational movements of the receptor binding domain (RBD)
that make neutralizing epitopes momentarily unavailable present immune escape routes for …

The COVID‐19 pandemic has caused an unprecedented health crisis and economic burden
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of …